J

Johnson & Johnson

Makes prescription drugs and medical devices

Employee & Labor Relations Investigations Manager

Full-TimeUpdated on 10/23/2026Deadline 11/4/26
CZK1.2M - CZK2M+ Annual target bonus
Senior
Bachelor's
Prague, Czechia
Hybrid
People & HRHR Generalist & Employee Relations

About the job

Requirements
  • A bachelor's degree in social sciences, law, human resources, humanities, business, or a related field, or equivalent professional experience.
  • A minimum of five years of relevant experience in employee relations, labor relations, or human resources.
  • Experience conducting investigations in a corporate environment, preferably human resources investigations.
  • Ability to manage relationships effectively and collaborate with a range of stakeholders on sensitive matters.
  • A strong background in continuous improvement and process excellence.
  • Ability to learn, interpret, and apply relevant legal, regulatory, and internal requirements across the countries in scope, engaging local counsel where appropriate, together with a strong understanding of investigation practices and broader employee relations and labor relations work.
  • Excellent investigative skills and a strong commitment to fairness and integrity, supporting objective and unbiased investigations.
  • Strong analytical and problem-solving abilities.
  • Strong organizational and prioritization skills, with the ability to plan and manage multiple investigations and employee relations matters simultaneously, balance competing deadlines and stakeholder needs, and deliver timely, accurate, and high-quality work.
  • Excellent oral and written communication and interpersonal skills, with the ability to influence and build relationships at all levels.
  • Ability to operate effectively in ambiguous situations and manage multiple cases and investigations in a fast-paced environment.
  • Proficiency in English is required.
  • Ability to manage and analyze data while exercising discretion when handling sensitive employee information and circumstances.
  • Required skills include continuous improvement, employee relations law, and stakeholder management.
Responsibilities
  • Assess complaints and determine the scope and nature of each investigation.
  • Conduct thorough, objective end-to-end investigations into employee relations matters, including harassment, discrimination, bullying, and other workplace concerns, to identify relevant evidence, reach findings and conclusions, and recommend appropriate resolutions to the business. Apply global and EMEA guidance and use available company artificial intelligence tools and solutions to improve efficiency.
  • Ensure the timely and fair resolution of investigations while maintaining high standards of investigative practice.
  • Prepare clear and robust investigation reports in accordance with applicable requirements.
  • Engage external counsel where required to support compliance with applicable requirements.
  • Primarily manage investigations across the Cluster and, as required, support Corporate employee relations and labor relations investigations with an EMEA focus, particularly matters involving cross-country elements that require specific expertise.
  • Manage sensitive cases effectively while balancing competing priorities and workload demands.
  • Manage a broad range of employee relations cases, from routine issues to complex and sensitive matters, prioritizing them appropriately and ensuring compliance with applicable service-level agreements and case-management metrics.
  • Provide advice and support on selected non-investigation employee relations matters, including performance, discipline, and other employment matters, as required based on Cluster priorities, while maintaining complete, accurate, and timely records in the case-management system.
  • Lead engagement with relevant country and Cluster stakeholders and coordinate communications at all appropriate stages of each investigation.
  • Build strong relationships and collaborate with relevant Global Shared Human Resources stakeholders, the Global Law Organization, external counsel, and cross-functional teams across the Cluster to address and resolve employee relations concerns effectively.
  • Act as a trusted advisor to business leaders, providing guidance and robust recommendations on workplace and employee relations concerns.
  • Collaborate with employee relations and labor relations teams involved in cross-country investigations to ensure adherence to local requirements.
  • Align and collaborate with the employee relations and labor relations team across the Cluster to ensure consistent case coordination.
  • Work closely with other employee relations and labor relations team members supporting investigations, demonstrating effective teamwork and partnership.
  • Lead the EMEA employee relations and labor relations Investigations Community of Practice, building on established regional efforts to strengthen alignment, consistency, efficiency, and compliance with investigation metrics, while collaborating with global and other regional employee relations and labor relations teams.
  • Stay informed about employment laws and regulations relevant to investigations across the Cluster to help ensure that investigation and employee relations practices align with applicable legal requirements.
  • Foster a culture of excellence in employee relations investigations and case management across the Cluster.
  • Implement best practices, capabilities, processes, and tools for employee relations work to support continuous improvement and consistently high standards.
  • Demonstrate understanding of artificial intelligence concepts and frameworks, including awareness of responsible and ethical artificial intelligence practices, experience generating effective prompts to boost efficiency and productivity, and awareness of artificial intelligence’s impact on the workforce.
Desired Qualifications
  • Fluency in at least one additional Cluster language is an advantage.
  • Preferred skills include coaching, commercial awareness, conflict resolution, consulting, corporate investigations, cultural competence, diplomacy, employee relations, human resources strategic management, human resources consulting, labor and employment law, mediation, people-centricity, people performance management, process improvements, talent management, technical credibility, and union relationships.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.